We are extremely proud that our central involvement in designing, execution and analysis of of the Telix ZIRCON pivotal phase III study was recently recognised in The Lancet Oncology.
This prospective, open-label, multicentre study evaluated the clinical utility of [⁸⁹Zr]Zr-girentuximab PET–CT imaging for detection and characterisation of clear-cell renal cell carcinoma.
While the study design was authored by Dr. Andreas Kluge, founder of ABX-CRO, Dr. Volker Meyer, Director Clinical Operations, was significantly involved in planning and realisation of this first-ever conducted pivotal PET study with an 89Zr-labelled diagnostic antibody. Our dedicated Image Core Lab team, headed by Karl Schmidt was responsible for state-of-the-art image analysis.
We thank Telix pharmaceuticals for choosing ABX-CRO for this historical PET diagnostic trial and are delighted to see this work being published in one of the world’s highest-impact academic journals.
Read the full article here